Ascentage Pharma Group International American Depository Shares (AAPG) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, gaining 57.5% versus a loss of 60.1%. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.38 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | PCRX |
|---|---|---|
| Share price | $14.75 | $36.31 |
| Market cap | $1.38B | $1.45B |
| 1-day change | +1.37% | -0.22% |
| YTD return | -43.79% | +40.30% |
| 1-year return | -60.15% | +57.46% |
| 5-year return | — | -31.75% |
| P/E ratio (TTM) | — | 103.74 |
| Forward P/E | — | 10.50 |
| EPS (TTM) | $-2.26 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $726.41M |
| Revenue growth (YoY) | — | +3.63% |
| Net income (latest FY) | — | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | — | 2.64% |
| Net margin | — | 0.97% |
| 52-week high | $37.50 | $36.46 |
| 52-week low | $14.46 | $18.80 |
| Distance from 52-week high | -60.67% | -0.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +219.53% | -17.08% |
| Average volume | 6.37K | 1.03M |
| Shares outstanding | 93.39M | 39.91M |
| Employees | 828 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed AAPG by 117.6 percentage points over the past year.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
AAPG vs PCRX FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.38B for Ascentage Pharma Group International American Depository Shares (AAPG).
Which stock has performed better over the past year, AAPG or PCRX?
PCRX returned +57.46% over the past 12 months, compared with -60.15% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.